GINKGO BIOWORKS

Grow with Ginkgo
Q3 2026 Update & Business Review

November 5, 2026



Disclaimer

FORWARD-LOOKING STATEMENTS

This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as Novo and OpenAI), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, including our increase of the total number of devices housed in Nebula's RACs and other expected features such as the automated nano-scale chemistry on RACs, multistep synthesis, safety-seq and biochemical screens, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations concerning increased government investment in and contracting for autonomous laboratory infrastructure, expectations regarding the development, performance and future enhancements of our platform and new product and service introductions, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek," "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release, and (xix) the risks relating to significant disruptions to our and our service providers' information technology systems or data security incidents. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, Ginkgo's quarterly report on Form 10-Q, once filed, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

INDUSTRY AND MARKET DATA

In this presentation, Ginkgo relies on and refers to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo management's estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information, and Ginkgo has not independently verified the accuracy or completeness of the information provided by the third-party sources.

USE OF NON-GAAP FINANCIAL MEASURES

Certain of the financial measures included in this presentation, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation included in this presentation for additional information regarding certain of the non-GAAP financial measures included in this presentation, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.

TRADEMARKS

This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and Ginkgo's use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

Agenda

Introduction
Jason Kelly, Co-Founder and CEO

Q3 2026 Financial Update
Steve Coen, CFO

Strategic Review
Jason Kelly, Co-Founder and CEO

Q&A Session
Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership

OUR MISSION

Make biology easier to engineer

IN 2026, GINKGO IS FOCUSING AND INVESTING TO WIN AUTONOMOUS LABS

Focusing Ginkgo's efforts on Autonomous Labs as the common platform for biotechnology research. Investing to extend our current progress in technology.

Demonstrating the capabilities of Autonomous Labs by decommissioning the majority of Ginkgo's lab benches, walk-up automation, and workcells and moving our three R&D services onto a single, large Autonomous Lab.

Booking new sales of Autonomous Labs in biopharma, national labs, and research universities.




Q3 2026 Key Financial Metrics

Revenue up from Q2’26; net loss and Adjusted EBITDA improved year-over-year

In millions of USD	Q3'26	Q3'25	% YoY
Revenue	$28	$29	(6%)
Net Loss from Continuing Operations	($41)	($73)	44%
Total Adjusted EBITDA	($22)	($53)	58%

Our improved cash burn allows us to invest in winning Autonomous Labs (Unaudited)

ANNUAL CASH BURN[1] ($M)



$285M

Ginkgo remains in a strong financial position with $285 million in cash, cash equivalents, and marketable securities with no bank debt as of Q3 2026

+$86M

Ginkgo has also set aside $86 million in restricted cash and marketable securities for customers and operating activities

(1) References to cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales and the $47M Pacific Northwest National Laboratory (“PNNL”) surety bond restriction. For a reconciliation of Cash burn, see the Appendix.

Agenda

Introduction
Jason Kelly, Co-Founder and CEO

Q3 2026 Financial Update
Steve Coen, CFO

Strategic Review
Jason Kelly, Co-Founder and CEO

Q&A Session
Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership

Q3 2026 Financial Summary (Unaudited)

	Three Months Ended September 30,			Nine Months Ended September 30,		
In millions of USD	**2026**	**2025**	**% YoY**	**2026**	**2025**	**% YoY**
Revenue [1]	$28	$29	(6%)	$67	$107	(37%)
Costs and operating expenses:						
Cost of other revenue [2]	2	3	(46%)	6	10	(42%)
Research and development [2]	27	51	(48%)	87	131	(33%)
General and administrative [2]	9	14	(32%)	33	49	(33%)
Stock-based compensation [3]	8	15	(49%)	33	52	(37%)
Depreciation and amortization	12	14	(12%)	37	44	(15%)
Restructuring charges [4]	0	1	(100%)	0	9	(100%)
Carrying cost of excess space (net of sublease income) [5]	14	14	(2%)	44	38	15%
Merger, acquisition and divestiture related expense (income) [6]	(0)	0	NM	1	(4)	NM
Other (income) expense, net [7]	(2)	(9)	(73%)	1	(11)	NM
Income taxes	(0)	0	NM	(0)	(0)	NM
Net loss from continuing operations	**(41)**	**(73)**	**44%**	**(174)**	**(210)**	**17%**
Total Adjusted EBITDA [8]	**(22)**	**(53)**	**58%**	**(101)**	**(122)**	**18%**
Capital expenditures (net of tenant improvement allowance)	**2**	**0**	**NM**	**7**	**4**	**70%**
Cash burn [9]	**(27)**	**(28)**	**3%**	**(120)**	**(124)**	**4%**

1. Nine months ended September 30, 2025 includes $7.5 million of non-cash revenue from a release of deferred revenue relating to the mutual termination of a customer agreement with BiomEdit.
2. The costs and operating expenses exclude expenses which are separately captioned below. Figures may not sum due to rounding.
3. Includes $0.1 million and $0.2 million in employer payroll taxes for the three months ended September 30, 2026 and 2025, respectively, and $1.4 million and $0.7 million for the nine months ended September 30, 2026 and 2025, respectively.
4. Restructuring charges primarily consist of employee termination costs from the reduction-in-force commenced in June 2024 and substantially concluded by December 31, 2025.
5. The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.
6. Represents transaction and integration costs directly related to mergers, acquisitions and divestitures, including: (i) legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses, (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions, and (iv) securities litigation costs.
7. Includes interest income, interest expense, gain and loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.
8. For a reconciliation of Adjusted EBITDA, see the Appendix.
9. References to cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales and the $47M PNNL surety bond restriction. For a reconciliation of Cash burn, see the Appendix.

Ginkgo reaffirms total cash burn guidance

In millions of USD	Historical	Outlook
	FY2025	**FY2026**
Total cash burn[(1)]	**($171)**	**($150) - ($125)**

(1) References to cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales and the $47M PNNL surety bond restriction. For a reconciliation of historical Cash burn, see the Appendix.

Property of Ginkgo Bioworks


Agenda

Introduction
Jason Kelly, Co-Founder and CEO

Q3 2026 Financial Update
Steve Coen, CFO

Strategic Review
Jason Kelly, Co-Founder and CEO

Q&A Session
Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership



OUR MISSION

Make biology easier to engineer

We believe...

1

Autonomous labs are having a moment. We sell them in two ways.

2

Blue chip early adopters are buying Ginkgo autonomous labs for their sites.

3

Cloud Lab services are growing: more biopharma customers + AI model training biodata demand from tech companies.

We believe...

1

Autonomous labs are having a moment. We sell them in two ways.

2

Blue chip early adopters are buying Ginkgo autonomous labs for their sites.

3

Cloud Lab services are growing: more biopharma customers + AI model training biodata demand from tech companies.

AI needs autonomous labs and autonomous labs need AI







Accelerate Autonomous Experimentation: Closed-loop autonomous laboratories can collapse discovery timelines by orders of magnitude and enable science at a truly industrial scale. Focus investments in robotics and automated laboratories, leveraging industry demand and federal R&D to ensure our scientific equipment industrial base is built on the world's best hardware and software and leads the charge in the coming scientific revolution.



1. Buy your own autonomous lab.

2. Use our autonomous lab in the cloud.

Property of Ginkgo Bioworks

Automation and Datapoints Summits



The Readiness & Enablement for Automated Labs Summit on 9/15



The Datapoints Summit on 9/16

We believe...

1

Autonomous labs are having a moment. We sell them in two ways.

2

Blue chip early adopters are buying Ginkgo autonomous labs for their sites.

3

Cloud Lab services are growing: more biopharma customers + AI model training biodata demand from tech companies.

Ginkgo building Autonomous Labs for MIT, Caltech, Maryland and Northwestern

AI-directed protein-engineering cloud lab receives $20 million from NSF

Northwestern facility will be nation's first open automated lab for designing, building and testing proteins

July 23, 2026 | By Amanda Morris



A new platform will let anyone with a computer conduct real lab experiments at the intersection of biology, AI, and robotics.



UMD Selected for $17.3M NSF Award to Establish Autonomous Biomanufacturing Laboratory

Ginkgo building Autonomous R&D Labs for Novo

Novo Nordisk Selects Ginkgo Bioworks to Build an Autonomous Lab, Expanding Partnership from R&D Services to Laboratory Robotics

Novo Nordisk's purchase of the autonomous lab deepens a multi-year relationship with Ginkgo and reflects growing industry momentum toward autonomous labs.

Ginkgo demonstrating Autonomous Labs in clinical settings


> **Gingko Bioworks Wins Up to $17.5 Million ARPA-H Subcontract for RNA Manufacturing**



2025: Ginkgo was selected to build the first autonomous lab for a national lab under the White House's Genesis Mission.







Breaking ground!

Facility

Microbial Molecular Phenotyping Capability (M2PC)

An SI-enabled, autonomous laboratory that expands PNNL's microbial science strengths





Pacific Northwest National Laboratory
124,871 followers
1w •

Today we welcomed the **U.S. Department of Energy Office of Science** for the groundbreaking of **Environmental Molecular Sciences Laboratory (EMSL)**'s Microbial Molecular Phenotyping Capability (M2PC), a first-of-its-kind autonomous laboratory that expands our microbial science strengths.

Learn how M2PC will accelerate microbial discoveries and help build the future of programmable biology: **https://bit.ly/3VUDfTV**

132 6 comments · 8 reposts


Our goal is to match the experience of building and expanding a manual lab
It takes less than a day to add new equipment to your Autonomous Lab



Ginkgo has the **largest** autonomous lab in the world.

You can use it as a cloud lab.





There is nothing like Nebula in the world today.

100+ protocols (30+ unique) in a single day.

100+ lab devices on an integrated setup.

Lab work running 24 hours a day.

Come visit!!!

https://calendly.com/ginkgo-bio/tour-ginkgo





We believe...

1

Autonomous labs are having a moment. We sell them in two ways.

2


Blue chip early adopters are buying Ginkgo autonomous labs for their sites.

3

Cloud Lab services are growing: more biopharma customers + AI model training biodata demand from tech companies.

Lab Data for AI, On-Demand

ADME, DRUG-seq cell perturbation and antibody data for Pharmaceuticals




GINKGO DATAPOINTS

Onshoring through automation.

Ginkgo’s goal is for its autonomous labs to outpace China’s R&D labor efficiencies

Ginkgo Datapoints ADME Services: Cheaper than WuXi by orders of magnitude. 22 unique ADME customers in Q3. 20 new to Ginkgo.

Absorption, Distribution, Metabolism, Excretion



Same assays trusted industry wide. Automated.

Data panel shows comparison for plasma protein binding versus published data from well-known global CRO, r=0.97

$199
per compound
ADME-One — 5 assays + PK projection + compound management

w/ partners Inductive Bio and Tangible Scientific


$2,000–5,000+
per compound
Traditional Western ADME vendors — panel only

$1,000–2,500+
per compound
Chinese CRO vendors — panel only

GEN Genetic Engineering & Biotechnology News

Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium

September 29, 2026



Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data



Integration puts Ginkgo's biological data generation services at the heart of the industry's most prominent AI-driven drug discovery network

Ginkgo Datapoints will provide discovery data generation services, including small molecule developability (ADME) and antibody developability testing, to TuneLab companies.

Are frontier AI labs buying bio data??

Yes!



Let’s grow the world we want to see

jason@ginkgobioworks.com

Agenda


Introduction
Jason Kelly, Co-Founder and CEO

Q3 2026 Financial Update
Steve Coen, CFO

Strategic Review
Jason Kelly, Co-Founder and CEO

Q&A Session
Moderated by Daniel Marshall, Sr. Manager of Communications and Ownership

APPENDIX



Adjusted EBITDA Reconciliation (Unaudited)

In millions of USD	Three Months Ended September 30, 2026	Three Months Ended September 30, 2025	Nine Months Ended September 30, 2026	Nine Months Ended September 30, 2025
Net loss from continuing operations [1]	**$ (41.0)**	**$ (73.4)**	**$ (174.4)**	**$ (209.9)**
Interest income, net	(3.1)	(5.7)	(9.9)	(17.9)
Income tax (benefit) expense	(0.3)	0.0	(0.2)	(0.2)
Depreciation and amortization	12.0	13.6	37.2	43.7
EBITDA	**$ (32.3)**	**$ (65.5)**	**$ (147.3)**	**$ (184.3)**
Stock-based compensation [2]	7.8	15.2	32.5	51.7
Restructuring charges [3]	0.0	0.7	0.0	8.8
Merger, acquisition and divestiture related expense (income) [4]	(0.0)	0.1	1.1	(4.5)
Loss (gain) on investments	0.3	(3.7)	(0.5)	0.2
Loss on equity method investment	2.0	0.0	6.7	0.0
Change in fair value of convertible notes	0.0	0.4	6.8	5.7
Adjusted EBITDA	**$ (22.3)**	**$ (52.7)**	**$ (100.8)**	**$ (122.3)**

1) All periods include non-cash revenue when earned, including $7.5 million recognized in the nine months ended September 30, 2025, pursuant to the release of deferred revenue related to the mutual termination of a customer agreement with BiomEdit.
2) Includes $0.1 million and $0.2 million in employer payroll taxes for the three months ended September 30, 2026 and 2025, respectively. Includes $1.4 million and $0.7 million in employer payroll taxes for the nine months ended September 30, 2026 and 2025, respectively
3) Restructuring charges primarily consist of employee termination costs from the reduction-in-force commenced in June 2024 and substantially concluded by December 31, 2025.
4) Represents transaction and integration costs directly related to mergers, acquisitions and divestitures, including: (i) legal, consulting and accounting fees associated with acquisitions, (ii) post-acquisition employee retention bonuses, (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions, and (iv) securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero for both the three months and nine months ended September 30, 2026 and 2025, respectively.

Cash Burn Reconciliation (unaudited)

In millions of USD	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
Net decrease in cash, cash equivalents and restricted cash	$ (46)	$ (94)	$ (86)	$ (449)
Net increase (decrease) in marketable securities	24	73	(14)	328
Net proceeds from ATM	(7)	(10)	(23)	(10)
Other adjustments [(2)]	2	3	3	7
Cash Burn [(1)]	**$ (27)**	**$ (28)**	**$ (120)**	**$ (124)**

(1) Cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales and the $47M PNNL surety bond restriction.

(2) Other adjustments primarily reflect changes in Company-imposed restricted cash, which are excluded from cash burn, and non-cash changes in the carrying value of marketable securities, and include rounding.

Cash Burn Reconciliation (unaudited)

	Twelve Months Ended December 31,	
In millions of USD	**2025**	**2024**
Net decrease in cash, cash equivalents and restricted cash	$ (393)	$ (383)
Net increase (decrease) in marketable securities	235	0
Net proceeds from ATM	(19)	0
Restricted stock movements	6	0
Cash Burn [1]	**$ (171)**	**$ (383)**

(1) Cash burn is defined as change in GAAP cash, cash equivalents, and marketable securities excluding Company imposed cash restrictions, as adjusted for unrealized equity gains and losses. Cash burn excludes net proceeds from ATM sales and the $47M PNNL surety bond restriction.